178 related articles for article (PubMed ID: 37813650)
1. [Expert consensus on endocrine therapy of breast cancer (2023 edition)].
Zhang SH; Wang XJ; Jiang ZF
Zhonghua Yi Xue Za Zhi; 2023 Oct; 103(38):2993-3001. PubMed ID: 37813650
[TBL] [Abstract][Full Text] [Related]
2. Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.
Lim E; Beith J; Boyle F; de Boer R; Hui R; McCarthy N; Redfern A; Wade T; Woodward N
Asia Pac J Clin Oncol; 2018 Oct; 14 Suppl 4():12-21. PubMed ID: 30288929
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
Rossi L; McCartney A; Risi E; De Santo I; Migliaccio I; Malorni L; Biganzoli L; Di Leo A
Clin Breast Cancer; 2019 Dec; 19(6):392-398. PubMed ID: 31358432
[TBL] [Abstract][Full Text] [Related]
4. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
[TBL] [Abstract][Full Text] [Related]
5. The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment.
Morrison L; Loibl S; Turner NC
Nat Rev Clin Oncol; 2024 Feb; 21(2):89-105. PubMed ID: 38082107
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
7. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.
Hong K; Yao L; Sheng X; Ye D; Guo Y
Oncol Res Treat; 2021; 44(10):557-567. PubMed ID: 34515204
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: does one size fit all?
Fedele P; Cinieri S
Future Med Chem; 2019 Jun; 11(11):1237-1239. PubMed ID: 31179740
[No Abstract] [Full Text] [Related]
10. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J; Ma CX
Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
[TBL] [Abstract][Full Text] [Related]
11. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Spring L; Bardia A; Modi S
Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
[TBL] [Abstract][Full Text] [Related]
12. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
O'Sullivan CC
Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
[TBL] [Abstract][Full Text] [Related]
13. Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer.
Loibl S; Furlanetto J
Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S70-S79. PubMed ID: 34930649
[TBL] [Abstract][Full Text] [Related]
14. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
Han Y; Wang J; Wang Z; Xu B
Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
[TBL] [Abstract][Full Text] [Related]
18. Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
Sharifi MN; Anandan A; Grogan P; O'Regan RM
Cancer; 2020 Aug; 126(15):3400-3416. PubMed ID: 32426848
[TBL] [Abstract][Full Text] [Related]
19. Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience.
Decker T; Seifert R; Bichler M; Birtel A; Fischer G; Nonnenbroich C; Dechow T
Oncol Res Treat; 2021; 44(9):443-449. PubMed ID: 34350900
[TBL] [Abstract][Full Text] [Related]
20. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]